Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Trials
Autori principali: Busard, Celine, Menting, Stef, van Bezooijen, Sun-Jine, van den Reek, Juul, Hutten, Barbara, Prens, Errol, de Jong, Elke, van Doorn, Martijn, Spuls, Phyllis
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288945/
https://ncbi.nlm.nih.gov/pubmed/28148280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-1777-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi